Vaxcyte, Inc. (PCVX)

NASDAQ: PCVX · IEX Real-Time Price · USD
26.16
+1.12 (4.47%)
Aug 18, 2022 4:00 PM EDT - Market closed
4.47%
Market Cap 1.55B
Revenue (ttm) n/a
Net Income (ttm) -142.70M
Shares Out 59.32M
EPS (ttm) -2.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 623,545
Open 24.76
Previous Close 25.04
Day's Range 24.44 - 26.24
52-Week Range 16.78 - 27.22
Beta 0.52
Analysts Buy
Price Target 48.28 (+84.6%)
Earnings Date Aug 9, 2022

About PCVX

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candi... [Read more...]

Industry Biotechnology
IPO Date Jun 12, 2020
CEO Grant Pickering
Employees 89
Stock Exchange NASDAQ
Ticker Symbol PCVX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for PCVX stock is "Buy." The 12-month stock price forecast is 48.28, which is an increase of 84.56% from the latest price.

Price Target
$48.28
(84.56% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update

-- Completed Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults -- -- Announcement of Topline Results from ...

Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

-- Company Receives FDA Fast Track Designation for VAX-24 in Adults -- -- Vaxcyte Completes Successful Pre-IND Meeting with FDA Regarding VAX-24 Pediatric Program, Supporting Path to Proceed Directly in...

Vaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study

Vaxcyte (PCVX) enrolls the last patient in the phase II portion of phase I/HH study, evaluating VAX-24 for preventing invasive pneumococcal disease and pneumonia in healthy adults.

Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Toler...

-- Company Expects to Announce Topline Results from the Phase 1 and Phase 2 Portions of the Proof-of-Concept Study in October or November 2022 -- -- Vaxcyte Also Dosed First Participants in Separate VAX...

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-D...

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential  new options for patients who do not respond to existing cancer immunotherapies ...

Other symbols: STRO

Vaxcyte to Present at the Jefferies Healthcare Conference

SAN CARLOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequen...

Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update

-- Company Continues to Advance Phase 2 Portion of the Ongoing Phase 1/2 Clinical Proof-of-Concept Study Evaluating VAX-24 in Adults Aged 18 to 64 for the Prevention of Invasive Pneumococcal Disease and...

Vaxcyte to Participate in Upcoming Investor Conferences in May

SAN CARLOS, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequenc...

Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference

SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseque...

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Ad...

-- Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned -- -- Company Expects to Announce Topline Results from...

Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

-- First Participants Dosed in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults -- -- VAX-24 Phase 1/2 Study Topline Safety, Tolerab...

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumoc...

-- Company Expects to Announce Topline Results from the Phase 1/2 Study   by the End of 2022 -- -- Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 --

Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

SAN CARLOS, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacteria...

Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SAN CARLOS, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacteria...

Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate

Vaxcyte Inc (NASDAQ: PCVX) priced its previously announced offering of common stock and pre-funded warrants at $20.00 per share, and $19.999 per underlying share, respectively. Vaxcyte is selling 2.5 mi...

Vaxcyte Announces Pricing of $100 Million Public Offering

SAN CARLOS, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacteria...

Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SAN CARLOS, Calif., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacteria...

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pne...

-- Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 -- -- VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide Bro...

Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 96%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Vaxcyte, Inc. (PCVX). While the effectiveness of this highly sought-after metric is questionable, the po...

Does Vaxcyte (PCVX) Have the Potential to Rally 89% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 89% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive t...

Vaxcyte to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed...

Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update

-- Company Expects to Submit VAX-24 IND Application to FDA in Q1 2022 -- -- Completed Manufacture of VAX-24 GMP Drug Product and GLP Toxicology Study --

Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors

FOSTER CITY, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed...

Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference

FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe...

Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference

FOSTER CITY, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe...